A new lung transplant machine that keeps organs alive outside the body could save four in every five donated lungs currently wasted in England and Wales. The XVIVO perfusion system, recommended by Nice for NHS use, warms donated lungs to body temperature and pumps a fluid mimicking blood plasma while ventilating them. This breakthrough technology allows transplant teams to monitor lung function, treat infections, drain fluid, and reinflate collapsed areas, significantly expanding the pool of viable organs.
How the Lung Transplant Machine Works
The machine mimics normal breathing and circulation, keeping lungs viable for up to six hours. This extended window enables thorough assessment and treatment, turning marginal lungs into transplant-ready organs. NHS Blood and Transplant data shows only 23% of donated lungs are currently used, with many declined due to quality concerns or logistical issues.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
Key Benefits of the Perfusion System
- Rescues up to 80% of donated lungs that would otherwise be discarded
- Reduces wait times for the 170 patients, including six children, on the UK transplant list
- Enables monitoring and treatment of organs before transplantation
- Addresses staffing and theater capacity constraints by extending organ viability
- Could unlock hundreds of additional transplants annually
Comparison of Current vs. Perfusion-Supported Transplants
| Metric | Current Standard | With XVIVO Perfusion |
|---|---|---|
| Lung utilization rate | 23% | Up to 80% potential rescue |
| Organ viability window | ~4 hours | Up to 6 hours |
| Transplant list deaths (urgent) | 20% within 1 year | Expected reduction |
| Adult waiting time | 1–2+ years | Shorter wait expected |
Nice Draft Guidance and NHS Implementation
The National Institute for Health and Care Excellence released draft guidance recommending a four-year NHS evaluation of the XVIVO perfusion system. This ensures all transplant centers, regardless of size or location, can benefit. Dr Anastasia Chalkidou, Nice's healthtech programme director, stated the machine should allow more lungs to remain available that otherwise would be discarded. The guidance also opens the door for pediatric cases, previously excluded from trials.
Impact on UK Transplant Rates
The UK currently has one of the poorest lung transplantation rates globally. Most adults wait a year for a transplant, and some wait two years or more. Up to a fifth of adults awaiting urgent transplants die within a year. By rescuing organs that are declined due to treatable issues like infection or fluid overload, this technology could dramatically reduce those numbers.
FAQ
How does the lung transplant machine keep lungs alive?
It warms donated lungs to body temperature and circulates a special fluid that mimics blood plasma while ventilating them to simulate normal breathing. This allows the lungs to remain viable for transplantation for up to six hours.
What percentage of donated lungs could be saved?
Nice estimates the XVIVO perfusion system could rescue four in five donated lungs that are currently unused—up to 80% of wasted organs.
Will this technology be available for children?
Yes, the Nice draft guidance now includes recommendations for pediatric cases, extending the potential benefit to the six children currently on the UK transplant list.
The XIVO perfusion system represents a major step forward in organ transplantation. By addressing both quality and capacity issues, it could transform NHS lung transplant outcomes and save hundreds of lives annually. As evaluation proceeds over the next four years, patients and clinicians alike await broader access to this life-saving technology.